Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
February 23 2021 - 8:30AM
Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare
pediatric liver disease company developing novel bile acid
modulators, today announced participation in the upcoming Cowen
41st Annual Health Care Conference March 1-4, 2021. Ron Cooper,
President and Chief Executive Officer of Albireo, will take part in
the New Drug Launches Panel on Wednesday, March 3, 2021 at 10:20am
ET. Members of the management team will also host meetings with
investors on March 2.
The Company will also be participating in the H.C. Wainwright
Global Life Sciences Conference March 9-10, 2021. Simon
Harford, Chief Financial Officer, and Pamela Stephenson, Chief
Commercial Officer, will take part in a fireside chat on March 9 at
7am ET, which will be available on-demand on the Albireo Media
& Investors page ir.albireopharma.com. Ron Cooper and members
of the management team will also host meetings with investors on
March 9.
About AlbireoAlbireo Pharma is a clinical-stage
biopharmaceutical company focused on the development of novel bile
acid modulators to treat rare pediatric and adult liver diseases.
Albireo’s lead product candidate, odevixibat, is being developed to
treat rare pediatric cholestatic liver diseases with Phase 3
pivotal trials in PFIC, Alagille syndrome and biliary atresia. The
Company completed IND-enabling studies for new preclinical
candidate A3907 and plans to advance development in adult liver
disease. Albireo was spun out from AstraZeneca in 2008 and is
headquartered in Boston, Massachusetts, with its key operating
subsidiary in Gothenburg, Sweden. The Boston Business
Journal named Albireo one of the 2020 Best Places to Work
in Massachusetts for the second consecutive year. For more
information on Albireo, please
visit www.albireopharma.com.
Media & Investor Contacts:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comHans
Vitzthum, LifeSci Advisors, LLC., 617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From Apr 2024 to May 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
From May 2023 to May 2024